ESTAHealthcare · Medical DevicesThe 10 Wall Street analysts covering Establishment Labs Holdings, Inc. hold a median 12-month price target of $95 — +41.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 4 Nov 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Establishment Labs Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (93): Sales and profits are climbing, and climbing faster than before.
Issuance (36): The company has been issuing shares or taking on financing, diluting existing holders.
Size (35): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ESTA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +41.9% from it.
Of the 20 most recent actions, 5 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Oct 2026 | BTIG | Maintains | Buy | $103 → $93 |
| 29 Oct 2026 | BTIG | Maintains | Buy | — |
| 26 Oct 2026 | TD Cowen | Maintains | Buy | $117 → $95 |
| 26 Oct 2026 | TD Cowen | Maintains | Buy | — |
| 15 Oct 2026 | TD Cowen | Reiterates | Buy | $117 |
| 15 Oct 2026 | TD Cowen | Reiterates | Buy | — |
| 1 Sept 2026 | BTIG | Reiterates | Buy | $103 |
| 1 Sept 2026 | BTIG | Reiterates | Buy | — |
| 13 Aug 2026 | Citigroup | Upgrade | Buy | $92 |
| 13 Aug 2026 | Citigroup | Upgrade | Buy | — |
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | — |
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | $84 → $95 |
| 6 Aug 2026 | BTIG | Maintains | Buy | — |
| 6 Aug 2026 | BTIG | Maintains | Buy | $96 → $103 |
| 6 Aug 2026 | Needham | Maintains | Buy | — |
| 6 Aug 2026 | Needham | Maintains | Buy | $86 → $95 |
| 3 Aug 2026 | TD Cowen | Maintains | Buy | $95 → $117 |
| 3 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 15 July 2026 | Mizuho | Maintains | Outperform | $100 → $105 |
| 15 July 2026 | Mizuho | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ESTA appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Establishment Labs Holdings, Inc. returned +35.5% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 98% of US stocks
Cheaper than 18% of US stocks
Cheaper than 1% of US stocks
Cheaper than 98% of US stocks
Higher than 80% of US stocks
Higher than 67% of US stocks
Higher than 83% of US stocks
Higher than 28% of US stocks
Higher than 17% of US stocks
Higher than 6% of US stocks
Higher than 35% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Establishment Labs Holdings, Inc. has a market value of $1.8B and an enterprise value of $2.1B.
Revenue in the twelve months to 30 June 2026: $245.8M. The latest quarter grew 33.9% year on year.
Net income over the same four quarters: −$38.9M, a −15.8% net margin.
Diluted earnings per share, trailing twelve months: $−1.31.
Free cash flow in the twelve months to 30 June 2026: −$41.6M.
Trailing P/E: −35.7×; forward P/E: −281.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Establishment Labs Holdings, Inc. employs 1,004 people — $245K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Establishment Labs Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Baron Discovery Fund reported initiating a position in Jersey Mike’s Subs, participating in Lyntris’s IPO, and selling its Wingstop position during the quarter to reallocate proceeds to other restaurant companies.
Why it matters — The excerpt describes portfolio activity in restaurant and defense companies but provides no direct information about Establishment Labs.
Seeking Alpha published the transcript of Establishment Labs Holdings Inc.’s Q3 2026 earnings call.
Why it matters — The transcript provides ESTA watchers with the company’s Q3 2026 earnings-call discussion to review.
Establishment Labs Holdings reported a third-quarter loss of $0.35 per share, compared with the Zacks Consensus Estimate of a $0.27 loss. The loss was narrower than the $0.38 per share reported a year earlier; the headline says revenue estimates were beaten.
Why it matters — ESTA watchers may note the quarterly per-share loss relative to estimates and the year-ago period, alongside the reported revenue-estimate beat.
Establishment Labs reported Q3 revenue of $72 million, up 33.9% year over year, citing U.S. market-share gains and international expansion. The company also generated positive free cash flow for the first time in its history.
Why it matters — The results highlight revenue growth and a milestone in cash generation for investors following ESTA.
Establishment Labs reported third-quarter 2026 financial results and highlighted a new supply agreement with NuSil to support long-term manufacturing capacity and future growth. It also said it received FDA approval for an additional smaller Motiva implant.
Why it matters — The supply agreement and FDA approval are updates on ESTA’s manufacturing capacity and product portfolio.
The 10 Wall Street analysts covering Establishment Labs Holdings, Inc. have a median 12-month price target of $95, with estimates ranging from $90 to $105. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Establishment Labs Holdings, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Establishment Labs Holdings, Inc. 74 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Establishment Labs Holdings, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (93 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +41.9% from the last close, and Ticker Nerd's factor model ranks Establishment Labs Holdings, Inc. 74 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Establishment Labs Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ESTA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $90 to $105 over the next 12 months.
Establishment Labs Holdings, Inc. returned +35.5% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Establishment Labs Holdings Inc. is a medical technology company focused on breast aesthetics and reconstructive plastic surgery.
The most recent item we track (Seeking Alpha, 4 Nov 2026): "Baron Discovery Fund Q3 2026 Portfolio Activity". Baron Discovery Fund reported initiating a position in Jersey Mike’s Subs, participating in Lyntris’s IPO, and selling its Wingstop position during the quarter to reallocate proceeds to other restaurant companies.
Establishment Labs Holdings Inc. is a medical technology company focused on breast aesthetics and reconstructive plastic surgery. Its core portfolio includes silicone gel-filled breast implants under the Motiva Implants brand, along with breast tissue expanders and related surgical technologies used in augmentation and reconstruction procedures. The company serves physicians, hospitals, and clinics through a combination of direct sales and distributor networks, supporting commercial activity across Europe, the Middle East, Africa, Latin America, Asia, and the United States. Establishment Labs Holdings Inc. also develops products and platforms designed to support surgical planning and procedural workflows in aesthetic and reconstructive care. Headquartered in Austin, Texas, the company plays a specialized role in the global medical device market by supplying devices centered on women’s health, breast reconstruction, and aesthetic surgery.
CEO Mr. Fillipo Peter Caldini · 1,004 employees · United States · https://www.establishmentlabs.com
